Welcome to ASCO Connection Discussion

Arsh Singh, MD
Jan 18, 2016 1:00 PM
In a 33 y/o caucasian woman with T2N0 Her 2 Positive invasive ductal carcinoma (both by IHC and FISH), ER 50% and PR negative, is it okay to use AC followed by T along with herceptin and pertuzumab  in the neoadjuvant setting?
Molecular Oncology Tumor Board
ASCO University
Jan 13, 2016 9:19 AM
Read more to answer the following questions: 1) What are the pathologic features that distinguish PEComa from the much more common leiomyosarcoma? 2) What is the role for cytotoxic chemotherapy in the treatment of metastatic or unresectable PEComa? 3) Are there any particular genetic targets...
Robert Glynne-Jones, MBBS
Dec 22, 2015 11:32 AM
Welcome to this discussion forum for the Rectal Cancer ASCO Tumor Board.  This course discussed an 82-year-old active female without systemic disease who is found to have microcytic anemia and weight loss. No other symptomatology. No family history of cancer. On exam she has no abdominal masses. No...
ASCO International Affairs
Dec 10, 2015 2:41 PM
More than 80 doctors, nurses and medical students attended the Multidisciplinary Cancer Management Course (MCMC) held in São Paulo, Brazil in August of 2015. ASCO partnered with the Instituto do Câncer do Estado de São Paulo (ICESP) to present the two-day course which featured interactive sessions...
Molecular Oncology Tumor Board
ASCO University
Dec 02, 2015 10:12 AM
Read more to answer the following questions: 1) Who should get routine molecular testing at diagnosis for NSCLC and what tests should be performed? 2)  Given this patient’s age and smoking history are you surprised at the finding of an EGFR mutation? 3) What is the most appropriate initial...


Tweets from ASCO

Tweets from Oncology Community